SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Inclusion Criteria: * 1 Subjects must have histological confirmation of relapsed or refractory Hodgkin lymphoma (HL). 2 12 to 75 years of age. 3 ECOG performance of less than 2. 4 Life expectancy of at least 3 months. 5 Subjects with lymphoma must have at least one measureable lesion \>1 cm as defined by lymphoma response criteria. 6 Subjects must have received at least four prior chemotherapy regimen, and must be off therapy for at least 4 weeks prior to Day 1. Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months.Subjects with Anti-PD-1 antibody are eligible which must be resistance. 7 Subjects must have adequate marrow, live, renal and heart functions. Exclusion Criteria: * 1 Subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications. 2 Serious uncontrolled medical disorders or active infections, pulmonary infection especially. 3 Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in 1 month . 4 Prior organ allograft. 5 Women who are pregnant or breastfeeding. 6 Women with a positive pregnancy test on enrollment or prior to investigational product administration. 7 Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.